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Abstract  
 
Objectives  
Poor adherence to immunosuppressive treatment is common in patients with systemic 
lupus erythematosus and may identify those with lupus nephritis (LN) who have a poorer 
prognosis.  Non-adherence has also been reported to be a potential adverse outcome 
predictor in renal transplantation (rTp). We investigated whether non-adherence is 
associated with increased rTp graft rejection and/or failure in patients with LN. 
 
Methods 
Patients with LN undergoing rTp in two major London hospitals were retrospectively 
included.  Medical and electronic records were reviewed for documented concerns of non-
adherence as well as laboratory biochemical drug levels. The role of non-adherence and 
other potential predictors of graft rejection/ failure including demographics, comorbidities, 
age at SLE and LN diagnosis, type of LN, time on dialysis prior to rTp and medication use 
were investigated using logistic regression. 
  
Results  
Out of 361 patients with LN, 40 had renal transplantation. During a median follow up of 8.7 
years, 17/40 (42.5%) of these patients had evidence of non-adherence. A total of 12 (30.0%) 
patients experienced graft rejection or failure or both.  In the adherent group 2/23 (8.7%) 
had graft rejection, whilst in the non-adherent this rose to 5/17 (29.4%, p=0.11). Graft 
failure was seen in 5/23 (21.7%) patients from the adherent group and 4/17 (23.5%) in the 
non-adherent group (p=0.89).  Non-adherent patients had a trend towards increased graft 
rejection, hazard ratio 4.38, 95% CI=0.73-26.12, p=0.11. Patients who spent more time on 
dialysis prior to rTp were more likely to be adherent to medication, p=0.01.  
 
Conclusion 
Poor adherence to immunosuppressive therapy is common and has been shown to 
associate with a trend towards increased graft failure in patients with LN requiring renal 
transplantation. This is the first paper to report that shorter periods on dialysis prior to 
transplantation might lead to increased non-adherence in lupus patients. 
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Key messages  
• Non-adherence to immunosuppressive medication following renal transplantation in 
patients with lupus nephritis is common 
• Non-adherence might lead to increased graft rejection following renal 
transplantation for lupus nephritis 
• Longer periods on dialysis prior to renal transplantation are associated with 
improved adherence post-transplantation 
  
Introduction 
 
According to the World Health Organization medication adherence is “the extent to which a 
person’s behaviour (taking medications, following a recommended diet and/or executing 
life-style changes) corresponds with the agreed recommendations of a health care provider 
1.” We and others have shown that adherence to medication is variable in patients with 
systemic lupus erythematosus (SLE), with poor adherence often affecting more than 50% of 
the patients;  this might potentially be associated with worse overall prognosis 2–4.  
 
Renal transplantation for patients with lupus nephritis is an increasingly utilised therapy for 
end stage renal failure (ESRF) 5,6. However, the sparsity of suitable donors and frequent 
allosensitisation of lupus patients due to receipt of blood products and prior pregnancies 
means that most patients spend significant time on dialysis before transplantation. Poor 
adherence to immunosuppressive therapy has been shown to associate with increased graft 
failure in renal transplant patients.  Up to 16% of graft losses are attributed, in part, to poor 
adherence 7,8.  
 
 It is recognised that in patients with renal transplantation non-adherence can lead to acute 
and chronic rejection, reduced renal function potentially necessitating return to dialysis and 
even death 9. Returning to dialysis after a failed renal transplant is associated with a 78% 
mortality risk compared to patients on the transplant waiting list receiving dialysis 10. 
However, despite the available evidence linking non-adherence to adverse outcomes in 
patients with transplantation, little specific is known regarding adherence in patients with 
lupus nephritis following renal transplantation and whether less adherent patients have 
worse outcomes. 
 In this study we investigated potential factors leading to non-adherence in patients with SLE 
who underwent renal transplantation for LN and whether evidence of non-adherence 
associates with increased renal graft rejection, defined as an acute deterioration in the graft 
function associated with specific histopathological changes in the graft; or failure,  defined 
as the need for dialysis or re-transplantation.    
 
Methods 
All patients with diagnoses of both SLE and renal failure leading to renal transplantation 
from two major London hospitals (University College London, UCLH, and Royal Free 
Hospital, RFH) since 1975 were retrospectively identified and included in this study 
analysing prospectively captured data. All patients fulfilled ≥4 of the 1982 revised 
classification criteria for SLE of the American College of Rheumatology 11 and we used the 
International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification 
system  to define the  histological class of lupus nephritis 12. Patients receiving a transplant 
prior to 1982 were retrospectively shown to fulfil the 1982 criteria.  
We retrospectively reviewed hospital electronic and paper records, correspondence with 
family practitioners and with other hospital physicians to identify any documented concerns 
about non-adherence to prescribed immunosuppressive treatment. Such concerns would 
usually be documented if the patients volunteered that they were not adherent to the 
medication themselves, by family members or admitting to this following direct questioning. 
Furthermore, in the United Kingdom repeat prescriptions are facilitated by the General 
Practitioner looking after the patients in the community. Therefore, if the patients do not 
renew their prescriptions in the community, the General Practitioner or the pharmacist will 
quickly become aware of this and will bring this to the attention of the clinical team for 
further evaluation. A recent article revealed that although patient reporting could detect 
even relatively infrequently missed tablets, drug monitoring could also identify severe non-
adherence 3. Thus, we also reviewed the trough blood levels recorded for patients on   
tacrolimus or ciclosporin and mycophenalate mofetil (MMF) to help ascertain evidence of 
non-adherence. As there is no standard biochemical definition of non-adherence for 
patients with a renal transplant, we took a realistic and pragmatic approach of defining non-
adherence as evidence of sub-therapeutic drug levels in routine measuring in >50% of the 
readings taken, at least 6 months after the renal transplantation to avoid levels taken during 
the initial introduction of the medication and individual dose adjusting. We used the 
percentage of sub-therapeutic trough levels of immunosuppressant medication  as a 
surrogate marker of poor adherence rather than trough level variability, as the former has 
been reported to be more strongly associated with graft rejection after kidney 
transplantation 7.  Finally, we examined potential associations with poor adherence 
including sex, ethnicity, age at SLE diagnosis, age at lupus nephritis diagnosis, age when 
dialysis was started, duration of SLE diagnosis to LN histological type of LN, time on dialysis 
prior to transplantation, other existing conditions such as diabetes mellitus, hypertension, 
dyslipidaemia and prior cardiovascular disease. The primary end point was renal graft 
rejection (defined as acute deterioration in graft function with rejection confirmed 
histopathologically) occurring >12 months from the transplantation. Secondary endpoints 
included renal graft failure (defined as need for dialysis or re-transplantation) and a 
composite endpoint of graft rejection and/or failure >12 months from the transplant.  As 
such, if graft failure was identified the patients were censored for the purposes of the 
secondary outcomes, but continued to be monitored for the primary endpoint of renal graft 
rejection in the second transplant. The study was a retrospective review of a long-term 
observational registry and in effect an audit for which University College London does not 
require formal ethical permission.  
Statistical analysis 
Categorical variables are presented as number and percentage whilst continuous variables 
are presented as mean and standard deviation (if normally distributed) or otherwise median 
and interquartile range. Comparisons between groups were performed using Student’s t-
test for normally distributed data or the Mann-Whitney U test for other data or Fisher’s 
exact test. Logistic regression was used to investigate the potential association between 
non-adherence and renal graft rejection or failure. A p<0.05 was considered significant. IBM 
SPSS version 25 (IBM Corp., Armonk, NY, USA) was used for statistical analyses. 
 
Results 
Three hundred and sixty-one patients with SLE were identified with lupus nephritis the vast 
majority biopsy confirmed (>90%), of who 40 had renal transplantation for lupus nephritis. A 
total of 17/40 (42.5%) patients were identified to be non-adherent to prescribed treatment 
for lupus nephritis (figure 1).  
 Figure 1: Flow diagram indicating the study population included in this cohort. 
As shown in table 1, the only significant difference between the adherent and non-adherent 
groups was the amount of time spent on dialysis with the adherent group spending 33 (27-
79) months on dialysis vs. the non-adherent group spending 17 (10-24) months on dialysis, 
p=0.01. There were no other significant differences in adherent and non-adherent patients. 
In particular, in this cohort there was no difference between the groups with regards to the 
age at SLE diagnosis or renal transplantation, gender, ethnicity, diagnosis duration,  
medication prescribed or donor source). In addition, there were no significant differences in 
other comorbidities between the two groups as shown in table 1 (all values p>0.05). 
Furthermore, there was no difference in adherence vs non-adherence patterns in patients 
who had received rTp prior to the year 2000 or after this time. Moreover, there was no 
difference in the group that had ever received azathioprine or ciclosporin, to a group that 
had never received either of these medications in terms of adherence (all values p>0.05). 
This would support that even if immunotherapeutic regimes were modified during the 
period of the study, this was unlikely to affect the pattern of adherence/non-adherence.  
One patient received three rTp in total and had rejection on the initial transplant. Two more 
patients received two rTp each. One had rejection on the initial graft whilst the second one 
did not have evidence of rejection either on the first or second graft.  
Recording a concern about non-adherence either following medical consultation or 
biochemically, supported a trend to increased graft rejection. During a median follow up of 
8.7 years, 17/40 (42.5%) of patients had evidence of non-adherence (table 1). A total of 12 
(30.0%) patients experienced graft rejection or failure or both.  From the adherent group 
2/23 (8.7%) had graft rejection whilst from the non-adherent group this was 5/17 (29.4%, 
p=0.11). Graft failure was seen in 5/23 (21.7%) patients from the adherent group and 4/17 
(23.5%) in the non-adherent group (p=0.89).  Using Logistic regression, non-adherent 
patients had a trend towards increased renal graft rejection (HR 4.38, 95% CI 0.73-26.12, 
p=0.11). There were no other significant predictors for graft rejection or failure or the 
composite endpoint as shown in table 2, apart from presence of class IV LN on pre-
transplant histology, which was associated with a significant risk of graft rejection/ failure.   
Interestingly, longer time on dialysis prior to the transplantation was associated with 
decreased non-adherence. For every additional month on dialysis non-adherence was 
reduced by HR 0.96, 95% CI 0.93-0.99, p=0.02. A receiver operating characteristic (ROC) 
curve (figure 2), identified that spending more than 25 months on dialysis was more likely to 
lead to better adherence with sensitivity 0.77, specificity 0.82 and good discrimination with 
AUC=0.76 supporting the idea that patients who spend more time on dialysis are more likely 
to be more adherent, and thus those with less time spent on dialysis prior to transplantation 
more likely to become non-adherent.  
 
Figure 2: Receiver operating characteristic (ROC) curve indicating supporting that dialysis 
time of more than 25 months prior to renal transplantation was associated with improved 
adherence (sensitivity 0.77, specificity 0.82 and good discrimination with AUC=0.76) 
 
Discussion                
In this study we considered the role of adherence to immunosuppressive treatment in 
patients with lupus nephritis requiring renal transplantation. We documented for the first-
time adherence patterns specifically for this cohort of patients and also investigated 
whether non-adherence was associated with increased risk for graft rejection and/or failure. 
Our results confirmed that more than 2/5 of our patients with lupus nephritis, even after 
renal transplantation, were considered to be non-adherent, either based on medical record 
evidence or biochemically based on drug level testing.  
What is  particularly noteworthy , is that once a concern about non-adherence was 
documented either in the medical notes or as evidenced with biochemical assays, there was 
a trend to more than a four-fold higher risk of graft rejection, indicating that poor 
adherence could have potentially significant adverse effects.  
As this was an observational retrospective study, it was not possible to investigate causality 
leading to non-adherence. However, our results  raise the strong possibility that patients 
who spend more time on dialysis are, in fact, more adherent to medication following 
transplantation. This is an important novel finding, as it may suggest that the time spent on 
dialysis has an indirect effect in encouraging better adherence post-transplant, perhaps 
because patients are more motivated to avoid returning to dialysis. With an increasing 
number of pre-emptive transplantation 6,13 it is possible that non-adherence could also 
increase and therefore the clinicians and other health care professionals should be aware 
and ever vigilant in recognizing this.  We have recently shown that increasing time on 
dialysis prior to rTp adversely affects prognosis specifically in lupus patients14, supporting 
previous literature in patients with renal disease of mixed aetiology receiving rTp 15 and 
therefore minimising the time on dialysis should remain the aim. However, particular 
attention should be paid to the patients who spent little or no time on dialysis to ensure 
that non-adherence does not compromise the beneficial effects of early transplantation.  
Limitations 
Although we included patients from two large hospitals in London over a four-decade 
period, we were only able to identify 40 eligible transplanted patients from an original 
cohort of 361 patients. This number  although is modest  is in line, or larger, than other 
similar published studies of LN 16,17. Our study was retrospective, however we endeavoured 
to avoid any bias by only considering strong pre-defined surrogates for non-adherence, such 
as clear documentation in the notes about poor adherence, or biochemical markers of non-
adherence, and a well-defined end-point of graft rejection and failure.  
Moreover, we had a mixture of Caucasian, Afro-Caribbean and South Asian patients and 
therefore our study results cannot be extrapolated to other populations. In view of this and 
also the relatively modest numbers in this study, we might have been underpowered to 
detect small but significant differences specific to individual ethnicity. As we focused our 
research only in the LN renal transplant patients, we are not able to comment about 
whether adherence in this cohort is higher or lower than the patients remaining on dialysis. 
In addition, the retrospective nature of the study did not allow us to screen accurately for 
depression, a  factor known to be associated with non-adherence in the general lupus 
population 18. Finally, despite one of the longest recorded follow up periods exceeding 422 
patient-years we only had 12 patients with graft rejection or failure, which may have 
impacted on identifying smaller potential associations with the other variables included in 
this study. 
Conclusion 
In conclusion, this study with a notably long-term follow up has shown that poor-adherence 
persists in patients with LN even after renal transplantation. It further shows that poor 
adherence may be associated with worse renal graft rejection and that shorter periods on 
dialysis prior to transplantation might lead to increased non-adherence. This is the first 
study to support such a conclusion. Further research needs to be undertaken collaboratively 
in multiple centres to identify the true adverse role of non-adherence in patients with renal 
transplant due to lupus nephritis. Such studies can also investigate further the factors 
leading to poor adherence in this cohort of patients.  
Identifying patients at risk of non-adherence utilising a combination of methods based on 
such factors is a key step. More importantly, patients at risk of, or with documented 
concerns about adherence should be closely followed up with regular biochemical testing, 
and a purposeful discussion about the likely consequences of non-adherence in the 
outpatient clinics may be necessary. Finally, enhanced education sessions highlighting the 
importance of immunosuppressive therapy adherence could be considered for all the lupus 
patients following renal transplantation but also importantly in anticipation of renal 
transplantation.  
 
Legends 
Figure 1: Flow diagram indicating the study population included in this cohort. 
Figure 2: Receiver operating characteristic (ROC) curve indicating supporting that dialysis 
time of more than 25 months prior to renal transplantation was associated with improved 
adherence (sensitivity 0.77, specificity 0.82 and good discrimination with AUC=0.76) 
Table 1: Patient demographic comparison between adherent and non-adherent groups.  
Table 2: Logistic regression hazard modelling investigating non-adherence and other 
potential predictors and graft-failure.  
  
  
 Adherence n=23 Non-adherence n=17 P value 
Sex/ female 20 (87%) 14 (82%) 0.70 
Ethnicity  
Caucasian 
Afro-Caribbean 
Asian 
 
8 
10 
5 
 
7 
5 
3 
 
0.46 
Age at SLE diagnosis 22 ± 9  21 ± 11 0.55 
Age at LN 27 ± 8 26 ± 9 0.63 
Time on Dialysis 33 (27-79) 17 (10-24) 0.01  
DM 2 (9%) 0 (0%) 0.50 
HTN 3 (13%) 6 (35%) 0.12 
Dyslipidaemia 3 (13%) 1 (6%) 0.62 
APLS 2 (9%) 2 (12%) 0.76 
CVS  2 (9%) 3 (18%) 0.43  
Histology type IV  9 (39%) 6 (35%) 0.55  
Donor living 8 (35%) 10 (59%) 0.20 
rTp time 
Before year 2000 
After year 2000 
 
6 (26%) 
17 (74%) 
 
2 (15%) 
15 (88%) 
 
0.41 
Age of ESRD 30 ± 9 32 ± 12 0.59  
Age at rTp 36 ± 11 34 ±12 0.57 
Graft rejection 2 (9%) 5 (29%) 0.11 
Graft failure 5 (22%) 4 (24%) 0.89 
Failure or rejection  5 (22%) 7 (41%) 0.21 
Table 1: Patient demographic comparison between adherent and non-adherent groups.  
 
  
 Hazard Ratio 
  
95% Confidence 
Interval 
P-value 
Gender male    
Rejection  -   
Failure 0.650 0.066- 6.410 0.650 
Rejection or Failure 0.418 0.043-4.024 0.450 
Ethnicity  0.758 0.333-1.727 0.510 
Rejection  0.697 0.268-1.810 0.458 
Failure    
Rejection or Failure 0.597 0.263-1.359 0.219 
Age at SLE Diagnosis    
Rejection  1.016 0.949-1.089 0.647 
Failure 1.064 0.976- 1.160 0.158 
Rejection or Failure 1.048 0.970-1.131 0.236 
Age at LN    
Rejection  0.979 0.880-1.089 0.696 
Failure 1.033 0.943-1.132 0.482 
Rejection or Failure 1.021 0.938-1.111 0.627 
Age starting dialysis    
Rejection  1.042 0.966-1.123 0.287 
Failure 1.052 0.980-1.129 0.165 
Rejection or Failure 1.044 0.976-1.116 0.209 
    
Time on dialysis    
Rejection  0.999 0.982-1.016 0.871 
Failure 1.001 0.987-1.015 0.860 
Rejection or Failure 0.998 0.985-1.012 0.829 
DM    
Rejection  -    
Failure 3.333 0.180-61.686 0.419 
Rejection or Failure 2.250 0.125-40.656 0.583 
HTN    
Rejection  2.500 0.389-16.049 0.334 
Failure 1.750 0.296-10.340 0.537 
Rejection or Failure 2.090 0.391-11.061 0.390 
Dyslipidaemia    
Rejection  1.200 0.101-14.195 0.885 
Failure 3.600 0.400-32.366 0.253 
Rejection or Failure 2.286 0.266-19.658 0.451 
APLS    
Rejection  1.133 0.096-13.440 0.921 
Failure 0.889 0.077-13.300 0.925 
Rejection or Failure 2.143 0.248-18.498 0.488 
CVS history    
Rejection  -   
Failure 2.000 0.256-15.623 0.509 
Rejection or Failure 1.238 0.166-9.253 0.835 
Histology type IV    
Rejection  -   
Failure 7.000 0.647-75.735 0.109 
Rejection or Failure  9.800 0.899- 106.845 0.061 
Donor source    
Rejection  1.619 0.309-8.478 0.568 
Failure 1.538 0.342-6.928 0.575 
Rejection or Failure 1.909 0.477-7.638 0.361 
Non-adherence    
Rejection  4.375 0.733-26.116 0.105 
Failure 1.108 0.248-4.944 0.893 
Rejection or Failure 2.520 0.632-10.054 0.190 
 
Table 2: Logistic regression hazard modelling investigating non-adherence and other 
potential predictors and graft-failure. Were a (-) is present it indicates too few events in that 
group to allow statistical modelling.  
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